To reach the next value inflection
LicenseRx asset brief
Design of Canine Antibodies for Targeted Therapeutics
Probability of Success
46% · grade B · Medium data confidence
Model PoS 46% (grade B, medium data confidence). Strongest signals: Data maturity, Indication pull. Biggest drag: IP position.
Data maturity (22%)
81
Clinical; in vivo data, efficacy signal.
IP position (16%)
45
No clear patent status in public data -- treat IP as unpriced until counsel confirms.
Modality feasibility (14%)
55
Cell/gene therapy -- high upside, heavy manufacturing and regulatory load.
Indication pull (14%)
76
Oncology, Immunology -- active buyer appetite.
Competitive whitespace (12%)
78
Under-served segment; crowded oncology field; multi-modal differentiation.
Translational evidence (12%)
62
Public evidence mentions: efficacy, in vivo.
Licensing readiness (10%)
94
Listed as available for licensing; established tech-transfer office; 1 public source link(s).
Unlock the full strategic deep dive
Cost to the next milestone, decisive data, relevant articles, and the partner-ready development plan for this asset.
View Operator access See what's included →